<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395016</url>
  </required_header>
  <id_info>
    <org_study_id>BPL-Nim-PC-1</org_study_id>
    <nct_id>NCT02395016</nct_id>
  </id_info>
  <brief_title>A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotech Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NanJing PLA 81 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotech Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor
      (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different
      indications. Nimotuzumab has been approved to treat squamous cell carcinoma of head and neck
      (SCCHN), glioma and nasopharyngeal carcinoma in different countries.The clinical phase Ⅲ
      trial designed to assess overall survival（OS）of the combination of Nimotuzumab administered
      concurrently with Gemcitabine in patients with RAS wild type of locally advanced or
      metastatic pancreatic cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor
      (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different
      indications. Nimotuzumab has been approved to treat squamous cell carcinoma of head and neck
      (SCCHN), glioma and nasopharyngeal carcinoma in different countries.The clinical phase Ⅲ
      trial designed to assess overall survival（OS）of the combination of Nimotuzumab administered
      concurrently with Gemcitabine in patients with RAS wild type of locally advanced or
      metastatic pancreatic cancer.Secondary objectives include time to
      progression（TTP）,progression-free survival（PFS）,Objective Response Rate（ORR）,Disease Control
      Rate（DCR）,Clinical Benefit Response（CBR）and safety.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival（OS）</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression（TTP）</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival（PFS）</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate（ORR）</measure>
    <time_frame>Once every eight weeks，up to 5.4 months</time_frame>
    <description>Appeared efficacy from the beginning until proven disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate（DCR）</measure>
    <time_frame>Once every eight weeks，up to 5.4 months</time_frame>
    <description>The number of cases in remission after being treated and the disease stabilized accounts the total percentage of the number of evaluable patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Response（CBR）</measure>
    <time_frame>Once a week,up to 5.4 months</time_frame>
    <description>Only evaluated the symptomatic patients in the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety of the treatment with Nimotuzumab and Gemcitabine (NCI Common Terminology Criteria for Adverse Events v4.03)</measure>
    <time_frame>Any adverse medical events occur from the beginning of receiving study drug to the end of treatment after 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab and Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Gemcitabine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nimotuzumab</intervention_name>
    <description>nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.</description>
    <arm_group_label>Nimotuzumab and Gemcitabine</arm_group_label>
    <other_name>Taixinsheng</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.</description>
    <arm_group_label>Nimotuzumab and Gemcitabine</arm_group_label>
    <arm_group_label>Placebo and Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.</description>
    <arm_group_label>Placebo and Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age:18-75 years old

          -  KPS≥60

          -  Histological or cytological diagnosis that are unsuitable for radical radiotherapy or
             surgical treatment of locally advanced or metastatic pancreatic adenocarcinoma (≥6
             months to the last adjuvant chemotherapy)

          -  Has at least one objective measurable lesion can be evaluated according to Response
             Evaluation Criteria in Solid Tumors1.1(Helical CT examination of the longest diameter
             of target lesions≥10mm, such as lymph node metastasis only need the shortest path
             ≥15mm)

          -  Life expectancy ≥12 weeks

          -  K-RAS tumor tissue detected as the wild-type

          -  Aspartate transaminase（AST）/aminotransferase（ALT）≤2.5×ULN，AST /ALT≤5×ULN（if liver
             metastases）；Total bilirubin≤2×ULN，Total bilirubin≤3×ULN（if liver metastases）；Absolute
             neutrophil count≥1.5×109/L；Blood platelet≥100×109/L；Hemoglobin≥90 g/L；Creatinine
             clearance≥60ml/min

          -  Volunteered to participate this study, written informed consent and has a good
             compliance

          -  Patients of childbearing age and their spouses are willing to take contraceptive
             measures

        Exclusion Criteria:

          -  Before this study had received the following treatments：As a means of anti-tumor
             palliative chemotherapy and molecular targeted therapy.Target lesion had received
             radiotherapy without progression.within 4 weeks or be participating in clinical trials
             of other therapeutic/ interventionist clinical trial.

          -  Undergone major surgery within 4 weeks.

          -  The brain metastasis or leptomeningeal metastasis.

          -  Has a history of malignancy other than the pancreatic cancer (except for the cured
             cervix in situ or basal cell carcinoma, and a five-year cure other cancers).

          -  The merger has symptoms of ascites and requires clinical treatment. Accompanied by
             other serious disease, including but not limited:Congestive heart failure which is
             difficult to control (NYHA III or IV), Unstable angina, Poorly controlled arrhythmia,
             Uncontrolled moderate to severe hypertension(systolic blood pressure（SBP）&gt;160 mm Hg or
             diastolic blood pressure（DBP）&gt;100 mm Hg).Active infection.Diabetes which is difficult
             to control.Has mental illness which impacts the informed consent and / or compliance
             program.HIV infection.There is serious illness that other researchers consider is
             unsuitable to participate this study.

          -  Known allergy to anti-EGFR antibody formulations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shukui qin, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>81th Hospital of PLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>jin li, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>shukui qin, MD, PHD</last_name>
    <phone>025-80864541</phone>
    <email>qinsk@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qiong wu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>qiong wu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230601</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhendong chen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>zhendong chen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>chunmei bai, PhD</last_name>
    </contact>
    <investigator>
      <last_name>chunmei bai, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>lin yang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>lin yang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PLA General Hospital (301 Hospital)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yi hu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>yi hu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Military Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianming xu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>jianming xu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>chunyi hao, PhD</last_name>
    </contact>
    <investigator>
      <last_name>chunyi hao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fuzhou General Hospital of Nanjing Military Region</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>xuenong ouyang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>xuenong ouyang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Tumor Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>jianwei yang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>jianwei yang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yuxian bai, PhD</last_name>
    </contact>
    <investigator>
      <last_name>yuxian bai, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangyin City People's Hospital</name>
      <address>
        <city>Jiangyin</city>
        <state>Jiangsu</state>
        <zip>214400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>qiong wang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>qiong wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Tumor Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jia chen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>jia chen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yang zhang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>yang zhang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiaotong University Affiliated Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>jun zhang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>jun zhang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>zhiqiang meng, PhD</last_name>
    </contact>
    <investigator>
      <last_name>zhiqiang meng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>tianshu liu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>tianshu liu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>deliang fu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>deliang fu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First People's Hospital Cancer Center, Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>liwei wang, PhD</last_name>
    </contact>
    <investigator>
      <last_name>liwei wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>zhaoshen li, PhD</last_name>
    </contact>
    <investigator>
      <last_name>zhaoshen li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wenchao liu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>wenchao liu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chengdu Military Region</name>
      <address>
        <city>Chendu</city>
        <state>Sichuan</state>
        <zip>610083</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>tao zhang, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>nong xu, PhD</last_name>
    </contact>
    <investigator>
      <last_name>nong xu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ying yuan, PhD</last_name>
    </contact>
    <investigator>
      <last_name>ying yuan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>hongming pan, PhD</last_name>
    </contact>
    <investigator>
      <last_name>hongming pan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>haijun zhong, PhD</last_name>
    </contact>
    <investigator>
      <last_name>haijun zhong, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>July 31, 2015</last_update_submitted>
  <last_update_submitted_qc>July 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

